(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 March 2016 (03.03.2016)

WIPO | PCT

(10) International Publication Number
WO 2016/033570 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *C07K 14/705* (2006.01)
A61K 35/17 (2015.01) *C07K 19/00* (2006.01)
C07K 14/725 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2015/047606

(22) International Filing Date:
28 August 2015 (28.08.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/043,273 28 August 2014 (28.08.2014) US
62/078,942 12 November 2014 (12.11.2014) US

(71) Applicant: **JUNO THERAPEUTICS, INC.** [US/US]; 307 Westlake Ave, North, Suite 300, Seattle, WA 98109 (US).

(72) Inventors: **CHEN, Yan**; c/o Juno Therapeutics, Inc., 307 Westlake Avenue North Suite 300, Seattle, WA 98109 (US). **SHAMAH, Steve**; c/o Juno Therapeutics, Inc., 307 Westlake Avenue North Suite 300, Seattle, WA 98109 (US). **PAZMANY, Csaba**; c/o Juno Therapeutics, Inc., 307 Westlake Avenue North Suite 300, Seattle, WA 98109 (US). **DUTTA-SIMMONS, Jui**; c/o Juno Therapeutics, Inc., 307 Westlake Avenue North Suite 300, Seattle, WA 98109 (US).

(74) Agents: **POTTER, Karen** et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2016/033570 A1

(54) **Title**: ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR CD19

(57) **Abstract**: Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.